IBTR Risk Estimation Downloads & RevenueIBTR Risk Estimation · App Store
IBTR Risk Estimation is #167 in Medical Paid in Japan and charting in 1 of 30 countries we track.
Updated 11 Nov 2026 · rankings refresh through the day
DeveloperYasuaki Sagara
CategoryMedical
Price500 JPY
Released
Rating★ 5.0 (1)
Version1.5
Age rating17+
First seen by us
25 Sep 2026
25 Sep 2026📈Entered the top 10📈Entered the top 100🆕First spotted by AppInsider📦Version 1.5🆕Released on the App Store
Full timeline · 5 events
- 📈IBTR Risk Estimation entered the top 10Top Paid · Medical · JP
- 📈IBTR Risk Estimation entered the top 100Top Grossing · Medical · JP
- 🆕IBTR Risk Estimation first spotted by AppInsider#29 in Top Paid · Medical · Japan
- 📦IBTR Risk Estimation version 1.5Updated the Age Rating settings.
- 🆕IBTR Risk Estimation released on the App Store
Collected from the stores by AppInsider since we first spotted the app. Dates are when we saw each change.
Rating
5.0 ★
1 ratings
Measured
Best rank now
#167
Medical PaidMeasured
IBTR Risk Estimation on the App Store
App details
App ID
6744888499
Publisher
Yasuaki Sagara
On the store since
Oct 2025
1 year on the store
Minimum OS
iOS 16.6+
iPhone 8 and later
Devices
iPhone · iPad
Universal purchase
Content rating
17+
1 content note below
Languages
1
EN
Size
9 MB
Content notesFrequent/Intense Medical/Treatment Information
Where it ranks now
Every top chart it appears in across 30 countries.
| Country | Charts | Rank |
|---|---|---|
| Japan | MedicalPaid | #167 |
Apps near IBTR Risk Estimation on the chart
Medical Paid, around #167.
Ratings
App Store, worldwide.
Rating
5.0 ★
1 ratings
Measured
Ratings
1
Measured
Review momentum
ⓘ How we measure thisNew ratings a week
under 1
4-week average
Lifetime rating
5.0★
recent stars not readable yet: new ratings are a tiny share of the total
Review momentum
20/100
faster than 0% of Medical apps
Review momentum (0-100) blends how fast the app collects ratings compared with other apps in its category (60%), whether that pace is speeding up (25%) and what recent raters give it (15%; recent stars well below lifetime pull it down). Ratings counts are read daily. A jump usually means a launch, a feature, ads or a new review prompt.
What users say about IBTR Risk Estimation
From recent reviews.
About IBTR Risk Estimation
This application is a tool to estimate the risk of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery.
It provides 10-year IBTR risk estimates and treatment effects, based on clinicopathological factors (age, pathological T stage, grade, margin status, lymphovascular invasion, hormone receptor status, HER2 status) and treatment options (radiation therapy, chemotherapy, endocrine therapy, anti-HER2 therapy). The application is available for both iPhone and iPad.
The tool was developed using a Cox proportional hazards model from a multicenter cohort of 8,938 patients and calibrated with treatment effects from the EBCTCG meta-analysis. It is designed for use in shared decision-making between patients and clinicians, as well as for educational purposes. The development methodology was presented at the 2025 ASCO Annual Meeting (Abstract No. 575) and published in JCO Clinical Cancer Informatics (Sagara et al., 2025). For further details, please refer to the publication.
Disclaimer
This application is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with the treating physician. The developers assume no legal responsibility for any outcomes resulting from the use of this application.
It provides 10-year IBTR risk estimates and treatment effects, based on clinicopathological factors (age, pathological T stage, grade, margin status, lymphovascular invasion, hormone receptor status, HER2 status) and treatment options (radiation therapy, chemotherapy, endocrine therapy, anti-HER2 therapy). The application is available for both iPhone and iPad.
The tool was developed using a Cox proportional hazards model from a multicenter cohort of 8,938 patients and calibrated with treatment effects from the EBCTCG meta-analysis. It is designed for use in shared decision-making between patients and clinicians, as well as for educational purposes. The development methodology was presented at the 2025 ASCO Annual Meeting (Abstract No. 575) and published in JCO Clinical Cancer Informatics (Sagara et al., 2025). For further details, please refer to the publication.
Disclaimer
This application is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with the treating physician. The developers assume no legal responsibility for any outcomes resulting from the use of this application.
Latest updates
1.5
Updated the Age Rating settings.